PFRM3: quote, dividends and indicators for Profarma Distribuição

Profarma Distribuição, traded on B3 under the ticker PFRM3, is a healthcare company that originated from Profarma Distribuidora de Produtos Farmacêuticos, founded in 1961 by Manoel Birmarcker in Rio de Janeiro. The company began its activities as a regional distributor of medicines and health and wellness products, including personal hygiene items, cosmetics and basic care products. Throughout the 1970s and 1980s, it expanded its customer base and corporate structure, entering into partnerships with large global and domestic pharmaceutical companies such as Bristol-Myers Squibb, Roche and Aché. Geographic expansion began in 1996 with the opening of the first branch in Minas Gerais, followed by the acquisition of KF Distribuidora in São Paulo in 1999, consolidating its presence in important pharmaceutical hubs in the country.

The process of operational modernization gathered pace from the 2000s onward. In 2001, the company implemented the integrated SAP system in all branches, a pioneering move in Brazil’s pharmaceutical distribution sector. Its specialty medicines operations began in 2002, supplying private clinics and hospitals, and were later reinforced by the acquisition of stakes in Prodiet Farmacêutica (hospital segment) and Arpmed (specialty products retail). In 2004, Profarma moved into the Northeast with a distribution center in Salvador, followed by new units in Pernambuco and Ceará, as well as the acquisition of distributor Dimper in Rio Grande do Sul in 2007, expanding its network of distribution centers across different regions of the country.

The IPO carried out in 2006 marked the company’s going public and the listing of its shares on B3, raising significant funds for the expansion and consolidation of its businesses. Also in 2006, the Profarma Institute for Social Responsibility was created, focused on supporting children and adolescents in vulnerable situations in the regions where the group operates. From 2013 onward, Profarma adopted an integrated operating model by entering the retail pharmacy segment through the acquisition of the Drogasmil, Farmalife and Tamoio chains in Rio de Janeiro and, in 2016, with the creation of d1000 Varejo Farma and the purchase of Drogaria Rosário, a major banner in the Center-West region. With this, the group consolidated a platform that combines distribution and retail, expanding its presence across the pharmaceutical sector value chain.

The current business model of Grupo Profarma is based on a vertically integrated platform with three complementary fronts: retail distribution of medicines and hygiene, beauty and cosmetics products, through Profarma Distribuição; distribution of specialty medicines in the institutional non-retail segment, through 4BIO; and retail pharmacy, through the d1000 network, composed of the Drogasmil, Farmalife, Tamoio and Rosário banners. This structure enables the capture of synergies between wholesale and retail operations, such as demand predictability, inventory optimization, greater bargaining power with the pharmaceutical industry, better use of logistics infrastructure and administrative gains from process centralization.

In retail distribution, the main segment in terms of revenue, Profarma Distribuição acts as a link between the industry and retail pharmacies, centralizing orders, credit management, inventory and logistics. As of December 31, 2025, the company operated 15 distribution centers in states such as Alagoas, Bahia, Espírito Santo, Distrito Federal, Goiás, Mato Grosso, Minas Gerais, Paraíba, Paraná, Pernambuco, Rio de Janeiro, Rio Grande do Norte, Rio Grande do Sul and São Paulo (Itapevi and São Carlos), totaling around 150,000 m² of storage and serving more than 4,500 cities. The company processes thousands of orders and SKUs daily, serves more than 50,000 customers per month and carries out tens of thousands of daily deliveries, with intensive use of third-party carriers and in-house logistics solutions through its subsidiary Locafarma.

The portfolio marketed by Profarma Distribuição and the d1000 network covers medicines in different categories and a broad range of non-medicine products. Among medicines, there are reference and similar products (branded drugs), generic medicines and OTC (over-the-counter) medicines, aimed at treating acute conditions that are easily self-diagnosed, such as pain, flu and gastric problems. In the non-medicine segment, the company works with personal hygiene, beauty and cosmetics products, dermocosmetics, convenience products, vitamins, supplements and related items. In retail, exclusive brands are a strategic pillar, with brands such as Nº21, GOnutri, Bem Básico, Mise, Bonnevi, Dfresh, Mini Moon, Polimix and Wissen, whose more than 390 products are manufactured by selected third parties and positioned across various categories with relevant market share.

The d1000 network, the group’s retail arm, had around 300 stores at the end of 2025, located in Rio de Janeiro, Distrito Federal and Mato Grosso, serving millions of active customers and pursuing distinct positioning among its banners in order to cover different regional socioeconomic profiles. In addition to selling medicines, hygiene and beauty products, dermocosmetics, convenience products and private-label brands, the group’s retail pharmacies offer pharmaceutical services such as disease testing, vaccination and basic first-care services. The network’s digital platform includes a marketplace, proprietary apps, a WhatsApp channel and CRM initiatives aimed at identifying and retaining customers, reinforcing its omnichannel presence. In 2025, the d1000 network recorded relevant participation in fast-growing categories such as GLP-1 inhibitor-based medicines for weight loss and for treating diseases linked to overweight and diabetes, which came to represent a significant portion of its sales.

In the institutional specialty market, the group returned to operating after having sold, in 2022, the Profarma Specialty joint venture to CM Hospitalar (Viveo). The return initially took place organically at the end of 2025 and was consolidated with the acquisition of 4BIO Medicamentos, completed in 2026, a company with more than two decades of experience in specialty medicines and a focus on high-complexity chronic patients, hospitals, clinics and health insurers. 4BIO has a broad portfolio in therapeutic areas such as oncology, infertility, hematology, hepatology, gynecology, nephrology, infectious diseases, orthopedics, pulmonology, rheumatology, endocrinology and dermatology, operating with its own distribution centers and ISO 9001 quality certification. This entry strengthens the group’s positioning in the fastest-growing segment of the pharmaceutical market, enabling it to offer integrated solutions to different links in the healthcare chain.

Profarma Distribuição’s customer base is diversified in terms of channels, including large chains, associations, franchises and independent pharmacies, as well as the d1000 network itself, whose purchases are mostly made via Profarma Distribuição. From a concentration standpoint, in 2025 only one customer exceeded 10% of the group’s consolidated net revenue: Raia Drogasil S.A., with around 18% of total sales, reflecting the strategic importance of large chains in the distribution model. Revenue is entirely derived from the sale of medicines and non-medicines in distribution and retail, complemented by promotional support, logistics and patient support program services developed in partnership with pharmaceutical laboratories.

Profarma Distribuição and the d1000 network operate in a highly regulated environment. The pharmaceutical sector in Brazil is regulated at the federal, state and municipal levels, with a central role played by the Ministry of Health and the National Health Surveillance Agency (ANVISA), which coordinates the National Health Surveillance System. The operation of distributors and drugstores is subject to a set of federal laws, decrees, resolutions and normative instructions, which govern everything from the registration, notification or enrollment of medicines and health products to the conditions for storage, transport, dispensing and pharmaceutical services provided in stores. In addition to federal legislation, there are specific rules issued by states and municipalities, requiring the company to maintain a permanent regulatory compliance structure to obtain and maintain the authorizations and licenses needed to carry out its activities in multiple jurisdictions.